F-star Therapeutics, Inc. (FSTX) Financial Analysis & Valuation | Quarter Chart
F-star Therapeutics, Inc. (FSTX)
FSTXPrice: $7.12
Fair Value: 🔒
🔒score
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 tri... more
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecif... more
Description
Shares
| Market Cap | $156.51M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | GB | CEO | Eliot Richard Forster |
| IPO Date | 2021-05-07 | CAGR | — |
| Employees | 84 | Website | www.f-star.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
FSTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $89.01M | P/E Ratio | -3.89 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 7.39 | P/B Ratio | 1.22 |
| P/CF Ratio | -4.35 | P/FCF Ratio | -5.6 |
| EPS | $-1.83 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 452.73% | Gross Margin | 1% |
| Operating Margin | -1.45% | Profit Margin | -1.48% |
| ROE | -0.45% | ROA | -0.25% |
| ROCE | -0.28% | Current Ratio | 6.98 |
| Quick Ratio | 7.17 | Cash Ratio | 6.47 |
| Debt/Equity | 0.14 | Interest Coverage | -36.39 |
| Altman Z Score | 0.67 | Piotroski Score | 3 |